December 18, 2018
Hisamitsu Pharmaceutical said on December 17 that it has filed a new drug application (NDA) with the US FDA for its transdermal patch formulation HP-3070 (asenapine) for the treatment of schizophrenia. HP-3070 is a systemic transdermal formulation developed by employing...read more